Poxel Announces its Participation at the 64th Annual Meeting of the Japan Diabetes Society
11 Maggio 2021 - 5:45PM
Business Wire
POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical
company focused on the development of innovative treatments for
metabolic disorders, including type 2 diabetes and non-alcoholic
steatohepatitis (NASH) today announced its participation at the
64th Annual Meeting of the Japan Diabetes Society (May 20-22,
2021).
Three presentations on Imeglimin will be included in an oral
session for large clinical studies in the afternoon (2:30 pm to
3:40 pm JST) of May 20. These presentations will be focused on the
analysis and interpretation of clinical data derived from Phase 2
and Phase 3 (TIMES program) trials with Imeglimin, Poxel’s novel
antidiabetic investigational drug, where Japanese patients with
type 2 diabetes (T2DM) were enrolled and studied:
- TIMES 2: Long-term Phase 3 study with Imeglimin as a mono- and
add-on therapies in Japanese T2DM
- Phase 2 and TIMES Post-hoc analysis of clinical studies in
Japan: efficacy & safety by age, kidney function and body mass
index
- Phase 2 and TIMES Post-hoc analysis of clinical studies in
Japan: efficacy by insulin secretion deficiency or insulin
resistance
Further, Imeglimin will also be discussed in Symposium 21, “New
therapies utilizing metformin and concomitant use of new drugs” on
May 22 (8:30 am to 11:30 am JST).
The event is dedicated to diabetes care and research. To learn
more about the event: https://site.convention.co.jp/64jds/en/
About Poxel SA
Poxel is a dynamic biopharmaceutical company that uses its
extensive expertise in developing innovative drugs for metabolic
diseases, with a focus on type 2 diabetes and non-alcoholic
steatohepatitis (NASH). In its mid-to-late-stage pipeline, the
Company is currently advancing three drug candidates as well as
earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead
product, targets mitochondrial dysfunction. Poxel has a strategic
partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan,
China, South Korea, Taiwan and nine other Southeast Asian
countries. A Japanese new drug application (J-NDA) is under review
by the Pharmaceuticals and Medical Devices Agency (PMDA) to request
approval for the manufacturing and marketing of Imeglimin for the
treatment of type 2 diabetes. After successfully completing a Phase
2a proof-of-concept trial for the treatment of NASH, which met its
primary endpoint and study objectives, for PXL770, a first-in-class
direct adenosine monophosphate-activated protein kinase (AMPK)
activator, Poxel plans to initiate a Phase 2b program in the second
half of 2021. PXL770 could also have the potential to treat
additional metabolic diseases. PXL065 (deuterium-stabilized
R-pioglitazone), a MPC inhibitor, is in a streamlined Phase 2 trial
for the treatment of NASH. Poxel also has additional earlier-stage
programs from its AMPK activator and deuterated TZD platforms
targeting chronic and rare metabolic diseases. The Company intends
to generate further growth through strategic partnerships and
pipeline development. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan. For more information, please visit:
www.poxelpharma.com
In the context of the COVID-19 outbreak, which was declared a
pandemic by the World Health Organization (WHO) on March 12, 2020,
the Company is regularly reviewing the impact of the outbreak on
its business.
As of the date of this press release, and based on publicly
available information, the Company has not identified the
occurrence of any material negative effect on its business due to
the COVID-19 pandemic that remains unresolved. However, the Company
anticipates that the COVID-19 pandemic could have further material
negative impact on its business operations. The worldwide impact of
COVID-19 may notably affect the Company’s internal organization and
efficiency, particularly in countries where it operates and where
confinement measures are implemented by the authorities. In
addition, COVID-19 may impact market conditions and the Company’s
ability to seek additional funding or enter into partnerships.
Particularly, delays in the supply of drug substance or drug
products, in the initiation or the timing of results of preclinical
and/or clinical trials, as well as delays linked to the
responsiveness of regulatory authorities could occur, which could
potentially have an impact on the Company’s development programs
and partnered programs. The Company will continue to actively
monitor the situation.
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210511005905/en/
Poxel SA Catherine David Investor Relations &
Communication Manager catherine.david@poxelpharma.com +33 7 64 57
61 78 Investor relations / Media - EU/US Trophic
Communications Stephanie May or Valeria Fisher poxel@trophic.eu +49
171 185 56 82 or +49 175 804 1816 Investor relations / Media -
France NewCap Emmanuel Huynh or Arthur Rouillé poxel@newcap.eu
+33 1 44 71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Apr 2023 a Apr 2024